You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProJohnson & Johnson (JNJ)
8 stories published on JNJ since June 2026. See all coverage.
News sentiment trend
Counts of positive, neutral, and negative news items over the last 90 days. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sentiment timeline
How news sentiment on Johnson & Johnson (JNJ) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Why this reading
The recent items weighing most on this reading, by direction and influence.
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Its Marathon Legal Fight
Direct news · Medium influence · Long term
Johnson & Johnson Stock: Early Phase 3 Win in Multiple Myeloma
Direct news · Medium influence · Long term
Goldman Sachs Backs J&J Pipeline Drug as Growth Driver
Direct news · Medium influence · Long term
FDA Approves Johnson & Johnson's Dual-Energy Ablation System for Cardiac Care
Direct news · Medium influence · Long term
Johnson and Johnson Wins Phase 3 Myeloma Trial for TALVEY as Cancer Pipeline Expands and Talc Risk Fades
Direct news · Medium influence · Long term
Direct news
The most recent stories naming JNJ directly, across all of our coverage.
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Its Marathon Legal Fight
Johnson & Johnson Stock: Early Phase 3 Win in Multiple Myeloma
Johnson and Johnson Named a Defensive Dividend Pick for Uncertain Markets
Johnson & Johnson Stock: Why JNJ Is Exploring a Sale of Its Orthopedics Business
Johnson & Johnson Stock: JNJ Faces Fresh Talc Risk as $45 Million Verdict Stands
Goldman Sachs Backs J&J Pipeline Drug as Growth Driver
FDA Approves Johnson & Johnson's Dual-Energy Ablation System for Cardiac Care
Johnson and Johnson Wins Phase 3 Myeloma Trial for TALVEY as Cancer Pipeline Expands and Talc Risk Fades
Indirect drivers in the news
Macro, commodity, FX and regulatory forces that have moved JNJ, with the stories behind each.
No indirect-driver news for JNJ in our coverage yet.
Also monitored for JNJ (no news in our coverage yet): FDA approvals & trial outcomes, Drug pricing / FDA / IRA.
See the full picture
Sign up free to track JNJ, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track JNJ for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.